RECRUITING

LCI-SAR-BSTS-CTDNA-001: Circulating Tumor DNA Liquid Biopsy in Sarcoma Patients

Talk to us

Conditions

Sarcomacirculating tumor DNAliquid biopsybone or soft tissue Sarcoma

Quick Navigation

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

The purpose of this research study is to see how well Low Pass Whole Genome Sequencing (LP-WGS) can detect circulating tumor deoxyribonucleic acid (ctDNA) in the blood of participants who have bone or soft tissue sarcoma (type of cancer).

Official Title

Prospective Clinical Evaluation of Circulating Tumor DNA Liquid Biopsy in Sarcoma Patients

Quick Facts

Study Start:2025-08-21
Study Completion:2030-01
Study Type:Not specified
Phase:Not Applicable
Enrollment:Not specified
Status:RECRUITING

Study ID

NCT06958107

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:Not specified
Sexes Eligible for Study:ALL
Accepts Healthy Volunteers:No
Standard Ages:CHILD, ADULT, OLDER_ADULT
Inclusion CriteriaExclusion Criteria
  1. 1. Written informed consent or assent when applicable from the participant, LAR, parent or legal guardian and HIPAA authorization for release of personal health information.
  2. 2. All ages allowed
  3. 3. Suspected or confirmed disease (must meet one of the criteria below):
  4. 1. Suspected bone or soft tissue tumor concerning for sarcoma (pending confirmation of sarcoma diagnosis)
  5. 2. Suspected lipomatous mass concerning for ALT or WDLS with planned surgery
  6. 3. Confirmed bone or soft tissue sarcoma meeting one of the criteria below:
  7. * Non-metastatic/Resectable sarcoma with either planned or currently receiving therapy
  8. * Metastatic or unresectable sarcoma, with planned or currently receiving therapy
  9. * Non-metastatic sarcoma under surveillance with no more than 1 year from completion of therapy
  1. * none

Contacts and Locations

Study Contact

Meg Lattanze
CONTACT
980-442-4239
Megan.Lattanze@advocatehealth.org

Principal Investigator

Johann Hsu, MD
PRINCIPAL_INVESTIGATOR
Wake Forest University Health Sciences

Study Locations (Sites)

Levine Cancer Institute
Charlotte, North Carolina, 28204
United States
Atrium Health Wake Forest Baptist Comprehensive Cancer Center
Winston-Salem, North Carolina, 27103
United States

Collaborators and Investigators

Sponsor: Wake Forest University Health Sciences

  • Johann Hsu, MD, PRINCIPAL_INVESTIGATOR, Wake Forest University Health Sciences

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2025-08-21
Study Completion Date2030-01

Study Record Updates

Study Start Date2025-08-21
Study Completion Date2030-01

Terms related to this study

Keywords Provided by Researchers

  • circulating tumor DNA
  • liquid biopsy
  • bone or soft tissue Sarcoma

Additional Relevant MeSH Terms

  • Sarcoma